PMID- 33301633
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Linking)
VI  - 75
IP  - 4
DP  - 2021 Apr
TI  - Efficacy of the fibrosis index for predicting end-stage renal disease in patients 
      with antineutrophil cytoplasmic antibody-associated vasculitis.
PG  - e13929
LID - 10.1111/ijcp.13929 [doi]
AB  - OBJECTIVE: Kidney involvement is a major manifestation of antineutrophil 
      cytoplasmic antibody-associated vasculitis (AAV) and may progress to end-stage 
      renal disease (ESRD), requiring renal replacement therapy. Unfortunately, there 
      is no reliable kidney-specific index for predicting the progression of renal 
      disease to ESRD. The fibrosis index (FI) reflects the degree of fibrosis in 
      chronic liver disease. This study aimed to investigate whether the FI at the time 
      of diagnosis could predict the development of ESRD in AAV patients. METHODS: We 
      retrospectively reviewed the medical records of 211 immunosuppressive drug-naive 
      AAV patients and extrapolated the cut-off FI value for predicting the development 
      of ESRD using receiver operating characteristic curves. The associations between 
      the FI and clinical outcomes, including mortality, relapse, and ESRD development, 
      were determined. RESULTS: Overall, 39 (18.5%) patients developed ESRD owing to 
      the progression of AAV-associated renal disease. The median FI was higher in AAV 
      patients with ESRD than in those without (1.61 vs 1.04; P = .001). The FI cut-off 
      was 1.72. The incidence of ESRD was higher in patients with FI >/= 1.72 at the time 
      of diagnosis than in those with an FI < 1.72 at the time of diagnosis (relative 
      risk: 4.655; 95% confidence interval: 2.242-9.662; P < .001). Kaplan-Meier 
      survival analysis revealed that patients with an FI >/= 1.72 at the time of 
      diagnosis exhibited significantly lower ESRD-free survival rates than those with 
      an FI < 1.72 at the time of diagnosis (P < .001). CONCLUSION: FI >/= 1.72 at the 
      time of diagnosis may be an independent predictive marker for ESRD in AAV 
      patients.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Pyo, Jung Yoon
AU  - Pyo JY
AUID- ORCID: 0000-0002-1866-6885
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Republic of Korea.
FAU - Ahn, Sung Soo
AU  - Ahn SS
AUID- ORCID: 0000-0002-9002-9880
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Republic of Korea.
FAU - Lee, Lucy Eunju
AU  - Lee LE
AUID- ORCID: 0000-0002-0897-661X
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Republic of Korea.
FAU - Choe, Ha Na
AU  - Choe HN
AUID- ORCID: 0000-0001-9446-1892
AD  - Department of Medicine, Yonsei University College of Medicine, Seoul, Republic of 
      Korea.
FAU - Song, Jason Jungsik
AU  - Song JJ
AUID- ORCID: 0000-0003-0662-7704
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Republic of Korea.
AD  - Institute for Immunology and Immunological Diseases, Yonsei University College of 
      Medicine, Seoul, Republic of Korea.
FAU - Park, Yong-Beom
AU  - Park YB
AUID- ORCID: 0000-0003-4695-8620
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Republic of Korea.
AD  - Institute for Immunology and Immunological Diseases, Yonsei University College of 
      Medicine, Seoul, Republic of Korea.
FAU - Lee, Sang-Won
AU  - Lee SW
AUID- ORCID: 0000-0002-8038-3341
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Republic of Korea.
AD  - Institute for Immunology and Immunological Diseases, Yonsei University College of 
      Medicine, Seoul, Republic of Korea.
LA  - eng
GR  - 6-2019-0184/Yonsei University College of Medicine/
GR  - HI14C1324/Korea Health Industry Development Institute/Republic of Korea
PT  - Journal Article
DEP - 20201220
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Antibodies, Antineutrophil Cytoplasmic)
SB  - IM
MH  - *Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/complications
MH  - Antibodies, Antineutrophil Cytoplasmic
MH  - Fibrosis
MH  - Humans
MH  - *Kidney Failure, Chronic/etiology
MH  - Retrospective Studies
EDAT- 2020/12/11 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/12/10 17:13
PHST- 2020/08/14 00:00 [received]
PHST- 2020/12/08 00:00 [accepted]
PHST- 2020/12/11 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/12/10 17:13 [entrez]
AID - 10.1111/ijcp.13929 [doi]
PST - ppublish
SO  - Int J Clin Pract. 2021 Apr;75(4):e13929. doi: 10.1111/ijcp.13929. Epub 2020 Dec 
      20.